Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests LDTs comprising MaterniT21 PLUS LDT, a noninvasive prenatal test NIPT to detect fetal chromosomal abnormalities; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers MaterniT21 GENOME test to detect genome-wide genomic deletions or duplications; HerediT cystic fibrosis CF LDT, a carrier screen test to identify individuals with CF or genetic mutations; and SensiGene fetal Rhesus D RhD LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample. In addition, the company provides a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; and additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand. It serves physicians and client laboratories. The company has collaboration with the Recombine Inc. Sequenom, Inc. was founded in 1994 and is headquartered in San Diego, California. As of September 7, 2016, Sequenom Inc. operates as a subsidiary of Laboratory Corporation of America Holdings